H5N8 vaccine

H5N8 vaccine
Vaccine description
TargetH5N8
Vaccine typeInactivated
Clinical data
Trade namesZoonotic Influenza Vaccine Seqirus
Routes of
administration		Intramuscular
ATC code
Legal status
Legal status

An H5N8 vaccine is an influenza vaccine intended to provide acquired immunity against H5 subtype influenza A viruses.[1] It is given via Intramuscular injection.[1]

Zoonotic influenza vaccine Seqirus

Zoonotic influenza vaccine Seqirus is authorized for use in the European Union.[1] It contains a flu strain called A/Astrakhan/3212/2020 (H5N8)-like strain (CBER-RG8A) (clade 2.3.4.4b).[1] Zoonotic influenza vaccine Seqirus was considered to be the best candidate to provide protection against circulating H5 influenza A strains.[1]

The most common side effects include reactions at the site of injection (swelling, pain, redness and hardening of the skin), myalgia (muscle pain), headache, tiredness, chills and feeling generally unwell.[1]

Zoonotic Influenza Vaccine Seqirus H5N8 is indicated for active immunization against H5 subtype influenza A viruses in adults 18 years of age and older.[1]

Society and culture

The European Commission arranged for a supply of zoonotic influenza vaccine.[2]

References

  1. ^ a b c d e f g h "Zoonotic Influenza Vaccine Seqirus EPAR". European Medicines Agency (EMA). 9 October 2023. Retrieved 26 September 2024. Text was copied from this source which is copyright European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  2. ^ "Commission secures access to 665,000 doses of zoonotic influenza vaccines". European Commission (Press release). 11 June 2024. Retrieved 26 September 2024.


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.